Pharmacokinetics of single oral doses of apricitabine, a novel deoxycytidine analogue reverse transcriptase inhibitor, in healthy volunteers

Clinical Drug Investigation

Volumn 26, Issue 5, 2006, Pages 279-286

  Holdich, Tom ^a   Shiveley, LeeAnn ^b   Sawyer, James ^c,d  

^a Shire Pharmaceuticals   (United Kingdom)

^b SHIRE   (United States)

^c Prism Ideas   (United Kingdom)

^d Avexa   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

APRICITABINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HALF LIFE TIME; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MYALGIA; MYASTHENIA; NORMAL HUMAN; PRIORITY JOURNAL; RHINITIS;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; SEX FACTORS; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 33744903369     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200626050-00005     Document Type: Article

References (14)

1. Dybul M, Fauci AS, Bartlett JG, et al. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137: 381-433
2. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society: USA Panel. JAMA 2002; 288: 222-35
3. Blaise P, Clevenbergh P, Vaira D, et al. HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice. Acta Clin Belg 2002; 57: 191-201
4. Taylor DL, Ahmed PS, Tyms AS, et al. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]. Antivir Chem Chemother 2000; 11: 291-301
5. Cahn P, van Leeuwen R, Sawyer J, et al. Tolerability and anti HIV-1 activity of SPD754 in 10 days monotherapy in treatment naive patients [abstract no. A-3093]. Proceedings and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003, Washington, DC
6. Collins P, Shiveley L, Anderson C, et al. Analysis of the genotypes of viruses isolated from patients after 10 days' monotherapy with SPD754 [abstract no. 526]. 11th Conference on Retroviruses and Opportunities Infections; 2004 Feb, San Francisco (CA)
7. Cassetti I, Cahn P, Adams J, et al. Slope of viral load decline and steady state pharmacokinetics of SPD754 monotherapy administered once or twice daily in treatment naive individuals [abstract no. 11.4]. Abstracts of the 9th European AIDS Conference; 2003 Oct 25-29; Warsaw, Poland
8. Smith PF, Forrest A, Ballow CH, et al. Absolute bioavailability and disposition of (-) and (+) 2′-deoxy- 3′-oxa-4′-thiocytidine (dOTC) following single intravenous and oral doses of racemic dOTC in humans. Antimicrob Agents Chemother 2000; 44: 1609-15
9. Blum MR, Liao SHT, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85: 189-94
10. Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166: 480-5
11. Hartman NR, Yarchoan R, Pluda RV, et al. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990; 47: 647-54
12. Klecker Jr RW, Collins JM, Yarchoan RC, et al. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol 1988; 28: 837-42
13. van Leeuwen R, Lange JM, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992; 6: 1471-5
14. Adams J, Sawyer J, Shiveley L, et al. SPD754 triphosphate pharmacokinetics following administration of SPD754 capsules [abstract no. 599]. 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb, San Francisco (CA)